Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | TOP1 | P11387 | 4/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869453 | 0.79 | HTT (0.45) | TOP1CYP3A4CYP2C19CYP2D6KDM4E | |
| SCHEMBL30912061 | 0.76 | CYP1A2 (0.53) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL28529317 | 0.76 | CYP1A2 (0.53) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL30292263 | 0.73 | ZDHHC7 (0.41) | HTR1ATOP1CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL11855598 | 0.69 | TSHR (0.42) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL209984 | 0.69 | NPC1 (0.56) | CYP3A4KDM4E | |
| SCHEMBL30292293 | 0.68 | TSHR (0.39) | HTR1AKDM4E | |
| SCHEMBL11224164 | 0.67 | SMPD1 (0.44) | CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL2802608 | 0.67 | PDE4D (0.56) | HTR1ATOP1CYP3A4 | |
| SCHEMBL9413733 | 0.67 | ESR2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2019667-A2 | DETECTION AND IMAGING OF TARGET TISSUE | Barnes-Jewish Hospital (US) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007127958-A2 | DETECTION AND IMAGING OF TARGET TISSUE | BARNES-JEWISH HOSPITAL (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070258908-A1 | Detection and imaging of target tissue | KEREOS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070255117-A1 | ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE-DEPENDENT CONTRAST AGENTS | BARNES-JEWISH HOSPITAL (US) | 2007-11-01 | — | — | US | disclosed |
| US-7179449-B2 | Enhanced ultrasound detection with temperature-dependent contrast agents | BARNES-JEWISH HOSPITAL (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1039834-B1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050175541-A1 | Enhanced drug delivery | KEREOS, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20050079131-A1 | Emulsion particles for imaging and therapy and methods of use thereof | KEREOS, INC. | 2005-04-14 | — | — | US | disclosed |
| EP-0920439-B1 | NUCLEIC ACIDS INTERNALLY-DERIVATIZED WITH A TEXAPHYRIN METAL COMPLEX AND USES THEREOF | PHARMACYCLICS INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020102216-A1 | Enhanced ultrasound detection with temperature-dependent contrast agents | KEREOS, INC. | 2002-08-01 | — | — | US | disclosed |
| EP-1039834-A4 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1039834-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6123923-A | ADMINISTERING A PATIENT A CONTRAST AGENT CONTAINING A STABILIZER, A PHOTOACTIVE AGENT, A GASEOUS PRECURSOR SUCH AS PERFLUORINATED COMPOUND OR GAS OR BOTH, AND SCANNING THE PATIENT USING ULTRASOUND IMAGING AND OPTICAL IMAGING | IMARX PHARMACEUTICAL CORP. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6022959-A | CONJUGATE BINDING A TEXAPHYRIN AND AN OLIGONUCLEOTIDE; FOR THE HYDROLYSIS OF RIBONUCLEIC ACID | PHARMACYCLICS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999030620-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5837866-A | Phosphoramidite derivatives of macrocycles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 1998-11-17 | — | — | US | disclosed |
| US-5633354-A | Phosphoramidite derivatives of texaphyrins | PHARMACYCLICS, INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5565552-A | Method of expanded porphyrin-oligonucleotide conjugate synthesis | PHARMACYCLICS, INC. (US) | 1996-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050175541-A1 | Enhanced drug delivery | LIPA, EPHA2, FABP1 | HTR1A 4338/4885TOP1 696/4885LTA4H 1188/4885 |
| US-20050079131-A1 | Emulsion particles for imaging and therapy and methods of use thereof | LIPA, PHOSPHO1, PLIN3 | HTR1A 4822/4885TOP1 1831/4885LTA4H 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.